T
Timothy B. Lowinger
Researcher at Bayer
Publications - 91
Citations - 4163
Timothy B. Lowinger is an academic researcher from Bayer. The author has contributed to research in topics: Antibody-drug conjugate & Conjugate. The author has an hindex of 26, co-authored 87 publications receiving 3917 citations.
Papers
More filters
Journal ArticleDOI
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm,Christopher A. Carter,Mark Lynch,Timothy B. Lowinger,Jacques Dumas,Roger A. Smith,Brian Schwartz,Ronit Simantov,Susan Kelley +8 more
TL;DR: The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature.
Patent
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
Scott Miller,Martin H. Osterhout,Jacques Dumas,Uday Khire,Timothy B. Lowinger,Bernd Riedl,William J. Scott,Roger A. Smith,Jill E. Wood,David E. Gunn,Holia Hatoum-Mokdad,Mareli Rodriguez,Robert Sibley,Ming Wang,Tiffany Turner,Catherine Brennan +15 more
TL;DR: In this article, the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases is described. But this is not related to our work.
Patent
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
Bernd Riedl,Jacques Dumas,Uday Khire,Timothy B. Lowinger,William J. Scott,Roger A. Smith,Jill E. Wood,Mary-Katherine Monahan,Reina Natero,Joel Renick,Robert Sibley +10 more
TL;DR: In this article, the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy, is described. But this is not the case in this paper.
Journal ArticleDOI
Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1
Toshiki Murata,Mitsuyuki Shimada,Sachiko Sakakibara,Yoshino Takashi,Hiroshi Kadono,Tsutomu Masuda,Makoto Shimazaki,Takuya Shintani,Kinji Fuchikami,Katsuya Sakai,Hisayo Inbe,Keisuke Takeshita,Toshiro Niki,Masaomi Umeda,Kevin Bacon,Karl Ziegelbauer,Timothy B. Lowinger +16 more
TL;DR: Optimization of the lead compound resulted in improvements in both in vitro and in vivo potency, and provided IKK-beta inhibitors exhibiting potent activity in an acute cytokine release model (LPS-induced TNFalpha).
Patent
Inhibition of raf kinase using substituted heterocyclic ureas
Jacques Dumas,Uday Khire,Timothy B. Lowinger,Holger Paulsen,Bernd Riedl,William J. Scott,Roger A. Smith,Jill E. Wood,Holia Hatoum-Mokdad,Jeffrey Johnson,Wendy Lee,Aniko Redman,Robert Sibley,Joel Renick +13 more
TL;DR: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se were discussed in this article, where the authors presented a method for treating cancer mediated by Raf kinases with substituted Urea compounds.